CHESTERBROOK, Pa. — Animas Corp., a Johnson & Johnson diabetes-care business, has announced plans to discontinue manufacturing and sale of insulin pumps, affecting about 400 workers, half of them in the Philadelphia area.
The company said Thursday that about 90,000 patients using Animas pumps will be offered the option of transferring to pumps made by Medtronic PLC.
Animas will cease sales of the Animas Vibe and OneTouch Ping pumps in the United States and Canada immediately and will eventually end operations in other countries.
The company said the decision was “extremely difficult” and followed “extensive exploration of all viable other options.”
Animas employs about 410 people, about half of whom work in Chesterbrook and at a manufacturing plant in West Chester.